SkinBioTherapeutics (LSE:SBTX) has announced a series of senior leadership changes aimed at enhancing financial governance and board oversight. The company has appointed Alyson Levett as a non-executive director and Chair of the Audit Committee, bringing additional audit and governance expertise to the board.
In parallel, Group Finance Director Emily Bertram has been promoted to Chief Financial Officer and appointed as an executive director, with both changes taking effect from 1 January 2026. As part of the reshuffle, Danielle Bekker has stepped down from the board but will continue to support the company in an external advisory capacity. SkinBioTherapeutics said the changes are intended to strengthen financial oversight at a time when management anticipates a particularly active year, potentially supporting improved execution of its growth and consolidation strategy in the skin health market.
Despite the governance enhancements, the company’s overall outlook continues to be shaped by financial headwinds, including ongoing losses and negative cash flows. Technical indicators point to bearish momentum, while valuation metrics remain under pressure due to a negative price-to-earnings ratio and the absence of a dividend yield. Collectively, these factors suggest a cautious stance among investors despite the board-level improvements.
More about SkinBioTherapeutics
SkinBioTherapeutics plc is a UK-based life sciences company focused on skin health, built around its proprietary SkinBiotix® platform derived from research at the University of Manchester. The group operates across five strategic pillars, with its most advanced activities in cosmetic skincare through a partnership with Croda, where SkinBiotix® is used as the active ingredient Zenakine™, and in gut–skin axis food supplements marketed under the AxisBiotix™ brand for inflammatory skin conditions. SkinBioTherapeutics is also pursuing a consolidation strategy through acquisitions of complementary skincare and cosmetic businesses and has been listed on AIM since 2017, with headquarters in Newcastle, UK.
Leave a Reply